Theriva Biologics, Inc. is a clinical-stage immuno-oncology company specializing in the development of oncolytic virus therapeutics aimed at treating cancer and related diseases with high unmet medical needs. Its innovative approach involves engineered oncolytic adenoviruses designed to selectively replicate within and destroy tumor cells while overcoming the physical and immunosuppressive barriers that hinder current cancer treatments. The company’s lead candidates include VCN-01, an oncolytic virus targeting solid tumors to promote tumor cell death and enhance immune response; SYN-004, aimed at preventing gastrointestinal damage from antibiotics; and SYN-020, an oral enzyme formulation addressing gastrointestinal and systemic conditions. Theriva’s therapies have potential applications across a broad range of difficult-to-treat cancers and may be combined with existing cancer therapies to improve patient outcomes. Established as a diversified clinical-stage biotechnology firm, Theriva Biologics plays a significant role in advancing novel immuno-oncology solutions within the biotechnology and pharmaceutical sectors.